×
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80

Diffusion Pharmaceuticals Stock Forecast, Price & News

$6.89
-0.15 (-2.13%)
(As of 07/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.80
$7.25
50-Day Range
$5.66
$8.21
52-Week Range
$5.10
$34.31
Volume
4,369 shs
Average Volume
31,625 shs
Market Capitalization
$14.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Diffusion Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
3.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($7.82) to ($6.91) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.79 out of 5 stars

Medical Sector

1144th out of 1,433 stocks

Pharmaceutical Preparations Industry

556th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive DFFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Diffusion Pharmaceuticals logo

About Diffusion Pharmaceuticals (NASDAQ:DFFN) Stock

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

DFFN Stock News Headlines

Diffusion Pharmaceuticals GAAP EPS of -$2.22
5 Stocks Halted In Tuesday's Session
Why Diffusion Pharmaceuticals Shares Are Falling
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DFFN
Employees
16
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/06/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Profitability

Net Income
$-24,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$17.13 per share

Miscellaneous

Free Float
2,002,000
Market Cap
$14.06 million
Optionable
Not Optionable
Beta
1.64














Diffusion Pharmaceuticals Frequently Asked Questions

Should I buy or sell Diffusion Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Diffusion Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DFFN, but not buy additional shares or sell existing shares.
View analyst ratings for Diffusion Pharmaceuticals
or view top-rated stocks.

How has Diffusion Pharmaceuticals' stock price performed in 2022?

Diffusion Pharmaceuticals' stock was trading at $15.25 on January 1st, 2022. Since then, DFFN shares have decreased by 54.8% and is now trading at $6.89.
View the best growth stocks for 2022 here
.

When is Diffusion Pharmaceuticals' next earnings date?

Diffusion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Diffusion Pharmaceuticals
.

How were Diffusion Pharmaceuticals' earnings last quarter?

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) announced its earnings results on Thursday, May, 12th. The company reported ($2.22) EPS for the quarter, missing analysts' consensus estimates of ($1.75) by $0.47.
View Diffusion Pharmaceuticals' earnings history
.

When did Diffusion Pharmaceuticals' stock split? How did Diffusion Pharmaceuticals' stock split work?

Diffusion Pharmaceuticals's stock reverse split on the morning of Tuesday, April 19th 2022. The 1-50 reverse split was announced on Tuesday, April 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 19th 2022. An investor that had 100 shares of Diffusion Pharmaceuticals stock prior to the reverse split would have 2 shares after the split.

Who are Diffusion Pharmaceuticals' key executives?

Diffusion Pharmaceuticals' management team includes the following people:
  • Dr. Robert J. Cobuzzi Jr., Pres, CEO & Director (Age 57, Pay $1.23M)
  • Mr. William Karl Hornung, Chief Financial Officer (Age 53, Pay $450.68k)
  • Mr. William Robert Elder J.D., Gen. Counsel & Corp. Sec. (Age 39, Pay $338.36k)
  • Dr. Christopher D. Galloway M.D., Chief Medical Officer (Age 51, Pay $539.59k)
  • Dr. David Randolph Jones M.D., Sr. Medical Advisor (Age 59)
  • Ms. Suzanne Cassidy, Sr. Director & Head of Quality Assurance
  • Dr. Jennifer Llewelyn Ph.D., Sr. Director & Head of CMC
  • Ms. Raven Jaeger M.S., Chief Regulatory Officer
  • Ms. Kelly Hoy, Director of Project Management
  • Mr. Harry Cook, VP of Clinical Operations

What other stocks do shareholders of Diffusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE) and Enerplus (ERF).

What is Diffusion Pharmaceuticals' stock symbol?

Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."

How do I buy shares of Diffusion Pharmaceuticals?

Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Diffusion Pharmaceuticals' stock price today?

One share of DFFN stock can currently be purchased for approximately $6.89.

How much money does Diffusion Pharmaceuticals make?

Diffusion Pharmaceuticals (NASDAQ:DFFN) has a market capitalization of $14.06 million. The company earns $-24,100,000.00 in net income (profit) each year or ($12.22) on an earnings per share basis.

How many employees does Diffusion Pharmaceuticals have?

Diffusion Pharmaceuticals employs 16 workers across the globe.

How can I contact Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The official website for Diffusion Pharmaceuticals is www.diffusionpharma.com. The company can be reached via phone at (434) 220-0718, via email at investorrealtions@diffusionpharma.com, or via fax at 434-220-0722.

This page (NASDAQ:DFFN) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.